tbuckley/cabot-search huggingface dataset:
LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
Authors: J-Y. Shih, J. Wang, Y. Wang, J. Wang, S-H. Lee, K. Azuma, T. Takahashi, J-L. Tan, C.C. Lin, S. Ganguly, V.H.F. Lee, P-L. Chu, S. Shah, B. Diorio, J.M. Bauml, B.C. Cho
Journal: Annals of Oncology (2023)
454P A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Authors: A. Ooki, T. Aoyama, K. Oba, K. Nishikawa, R. Kawabata, M. Honda, H. Maeda, M. Kanda, K. Sugiyama, A. Makiyama, K. Segami, M. Takahashi, Y. Shindo, T. Namikawa, T. Oshima, A. Katayama, K. Shiosakai, J. Sakamoto
Journal: Annals of Oncology (2023)
293P Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Authors: N.I. Valdiviezo Lama, I. Otoya Fernández, L.D.C. Chavez Jimenez, R.E. Ruiz, O. Coanqui Gonzales, M. Olivera, C. Velarde Navarrete, L.A. Mas Lopez
Journal: Annals of Oncology (2023)
367P Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Authors: J.H. Koh, C. Lim, L. Tan, A. Makmur, E. Gao, J.S.Y. Ho, A.J. Tan, A. See, B.K.J. Tan, L.F. Tan, B.Y.Q. Tan
Journal: Annals of Oncology (2023)
423P Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Authors: M. Ghosh, G. Balaram, S.M. Lingaraju, K. Raghavendrachar, R. Kodandapani, V. Erappareddy, V. Keriyappa, S.N. Ghorpade, S. Patil, S. Chiradoni Thungappa, S. Bhattacharjee, S. Papaiah Susheela, M. Naseer R, R. Dasgupta, S. Belagutti Jayappa, V. Ramaswamy, D. Hattangdi, A. Ravichandran, U. Bahadur, B.S. Ajaikumar
Journal: Annals of Oncology (2023)
529P Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Authors: T. Yamada, Y. Katayama, S. Watanabe, K. Watanabe, T. Takeda, Y. Chihara, S. Shiotsu, M. Hibino, T. Harada, K. Takayama
Journal: Annals of Oncology (2023)
510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02)
Authors: Y. Goto, K. Goto, T. Kubo, K. Ninomiya, S-W. Kim, M-J. Ahn, K. Nakagawa, H. Hayashi, J. Shimizu, D-W. Kim, J.C-H. Yang, C-H.S. Kuo, K.H. Lee, T-Y. Yang, K.M.C. Pereira, A. Taguchi, A. Ali, F-C. Cheng, R. Yonemochi, P.A. Jänne
Journal: Annals of Oncology (2023)
563P Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Authors: J. Zhou, L. Shen, D. Lv, K. Tang, D. Zhu, Y. Zhao, K. Wang, Y. Wang, L. Xing, J. Cui, L. Ding, X. Shi, J. Zheng, J. Zhou
Journal: Annals of Oncology (2023)
432MO Barriers and facilitators of home-based exercise intervention participation in Indonesian breast cancer patients: A nested qualitative study using COM-B model
Authors: Y.K. Astari, S.H. Hutajulu, Y.S. Prabandari, M.D.L.Q. Mozhaf, M.S. Hardianti, A.B. Hartopo, M.J. Allsop, S. Burke
Journal: Annals of Oncology (2023)
569P Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Authors: C-Y. Zhang, H. Sun, J-W. Su, X-H. Zhang, W-N. Feng, Y-L. Wu, J-J. Yang
Journal: Annals of Oncology (2023)
565P Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Authors: M.S.C. Li, K. Mok, G. Tsui, K.W.C. Lee, K.C. Lam, H.H.F. Loong, F. Mok, L.L. Chan, K. Yan, T.Y.J. Ng, D. Johnson, B. Lam, W. Wong, A. Chen, M.P. Lee, O. Chen, T.S.K. Mok
Journal: Annals of Oncology (2023)
570P First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Authors: W. Ji, D. Jiang, J. Zhang, H. Zhang, Q. Wang, S. Cang, X. Li, J. Tan, Y. Xiang, X. Li, A. Liu, S. Lu
Journal: Annals of Oncology (2023)
518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Authors: S. Kitazono, L. Paz-Ares, M-J. Ahn, A.E. Lisberg, B.C. Cho, G. Blumenschein, E. Shum, E. Pons-Tostivint, Y. Goto, K. Yoh, R. Heist, P. Baas, D. Planchard, M. Pérol, E. Felip, W-C. Su, H. Zebger-Gong, L. Lan, C. Liu, J. Sands
Journal: Annals of Oncology (2023)
590P A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Authors: B. Markman, B. Solomon, L.M. Nott, R. Roberts-Thomson, B. Hughes, N. Pavlakis, A. Davis, L.J. Brown, S. Parakh, D. Brungs, S.E. Bowyer, I. Nordman, R. Jennens, L. Warburton, S.J. Harris, E. Samuel, S. Ramanujam, A. Wang, M. Dumas, G. Gard
Journal: Annals of Oncology (2023)
496P Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Authors: S. Lu, J. Fang, A. Liu, X. Dong, Y. Yu, S. Han, Z. Zeng, R. Zhang, P. Lu, H. Shi, P. Tan, S. Fan, M. Shi, W. Su
Journal: Annals of Oncology (2023)
333MO Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study
Authors: D.H. Yoon, H. Cho, J.C.Y. Sheng, D.J. Kim, K-W. Kang, J-Y. Kwak, S-M. Tan, J-O. Lee, S.Y. Oh, H-S. Eom, Y.R. Do, S.H. Jeong, H.J. Kang, Y. Koh, U. Bunworasate, H.J. Kim, J-C. Jo, S-H. Kim, K. Kato, W.S. Kim
Journal: Annals of Oncology (2023)
LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study
Authors: Q. Zhou, X. Meng, L. Sun, D. Huang, N. Yang, Y. Yu, M. Zhao, W. Zhuang, Y. Hu, Y. Pan, M. Sun, J. Shan, R-H. Guo, Q. Chu, C. Xu, J. Lin, J. Huang, M. Huang, Y. Shen, Y-L. Wu
Journal: Annals of Oncology (2023)
514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2
Authors: C.K. Lee, J.P. Robichaux, P.A. Jänne, S-W. Kim, T.M. Kim, K. Kobayashi, D. Planchard, S. Sugawara, N. Yanagitani, T-Y. Yang, A. Markovets, P. Bhetaryia, L. Poole, Y. Rukazenkov, R.J. Hartmaier, J.C-H. Yang
Journal: Annals of Oncology (2023)
502P Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Authors: K. Tamura, H. Horinouchi, M. Miyake, K. Masuda, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2023)
512MO FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Authors: D. Planchard, P.A. Jänne, Y. Cheng, C.K. Lee, K. Laktionov, T-Y. Yang, Y. Yu, T. Kato, L. Jiang, B. Chewaskulyong, S. Lucien Geater, J-M. Maurel, C. Rojas, L. Havel, F.A. Shepherd, K. Tanaka, D. Ghiorghiu, E. Armenteros Monterroso, X. Huang, J.C-H. Yang
Journal: Annals of Oncology (2023)
448P Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Authors: S.H. Hutajulu, Y.K. Astari, M. Ucche, D.K. Paramita, R.H. Asdie, R.B. Pramono, M.S. Hardianti, K.W. Taroeno-Hariadi, I. Purwanto, J. Kurnianda
Journal: Annals of Oncology (2023)
LBA13 Dostarlimab + chemotherapy (CT) vs pembrolizumab + CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial
Authors: D.H. Lee, J.S. Ahn, S-H. Lin, M. Ulanska, G.A. Lopez, C-F. Chian, L. Cho, Z. Szijgyarto, N. Stjepanovic, S.M. Lim
Journal: Annals of Oncology (2023)
522P Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Authors: I. Nakachi, D. Fujimoto, R. Shibaki, E. Miyauchi, Y. Tsukita, Y. Sakata, N. Shingu, D. Arai, T. Kijima, M. Tamiya, S. Kawana, S. Hara, G. Saito, Y. Sato, S. Sakata, H. Matsumoto, T. Yamaguchi, N. Yamamoto
Journal: Annals of Oncology (2023)
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa
Authors: Kristina Navrazhina, Yael Renert-Yuval, Saakshi Khattri, Hassan Hamade, Marguerite Meariman, Elizabeth Andrews, Madeline Kim, Monali NandyMazumdar, Digpal S. Gour, Swaroop Bose, Samuel C. Williams, Sandra Garcet, Joel Correa da Rosa, Alice B. Gottlieb, James G. Krueger, Emma Guttman-Yassky
Journal: Journal of the American Academy of Dermatology (2023)
190P Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Authors: J. He, Y. Yang, S. Zhou, B. Zhang, Z. Han, T. Wu, Q. Qiao, H. Yang, X. He, N. Wang
Journal: Annals of Oncology (2023)
189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Authors: S. Yamamoto, C-Y. Lin, C. Rojas, F. Rivera Herrero, D.L.W. Kwong, M-H. Chen, Y. Zhang, L. Yu, S. Shah, P. Bhagia, L. Shen, J-M. Sun
Journal: Annals of Oncology (2023)
207TiP A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Authors: P.G. Bhargava, A. Ramaswamy, B. Dubashi, A. Kapoor, S. Srinivas, O. Shetty, R. Kaushal, A. Shah, V. Noronha, A.P. Joshi, N.S. Menon, C. Nashikkar, A. Gupta, B.K. Mishra, N. Sisodia, V. Pal, S. Kayal, K. Prabhash, V.S. Ostwal
Journal: Annals of Oncology (2023)

Chemotherapy is the mainstay of treatment in advanced gastroesophageal junction and gastric (GEJ/G) adenocarcinomas, with some additional role for targeted therapy and immunotherapy in select subsets. The choice of optimal chemotherapy in this setting remains undecided, especially with regard to the addition of docetaxel to a FOLFOX/CAPOX (doublet combination) backbone in improving outcomes. Additionally, there is also equipoise with regard to continuing palliative chemotherapy beyond six months in patients with these cancers. The DOC GC study in a multicentric open-label, randomised controlled phase III trial, in adults (age >=18 years) with unresectable/metastatic GEJ/G adenocarcinoma and adequate end-organ function. Patients will undergo randomization to one of two arms: Arm A (Doublet regimen)- modified CAPOX (3 weekly) or modified FOLFOX-7 ( 2 weekly) for a maximum of 6 months and then observation or Arm B (Tripet regimen): modified FLOT (5-FU/leucovorin /Oxaliplatin/Docetaxel) or DOX (docetaxel/oxaliplatin/capecitabine) every 2 weeks for a maximum of four months followed by Docetaxel (60mg/m2) every 3 weeks till disease progression, unacceptable toxicity, or patients choice The primary endpoint of the study is Overall survival (OS), as calculated by Kaplan-Meier method, while key secondary endpoints include Progression-free survival, adverse event rates, and quality of life. Next-generation sequencing is being conducted on all biopsy specimens and patient data will be classified as per the Asian Cancer Research Group classification of gastric cancers based on sequencing. Assuming the median OS with mFOLFOX/CAPOX is 11 months, the study with a power of 80% with a two-sided alpha of 5% requires 162 patients per arm to show a superiority in terms of OS of 5 months with modified FLOT/DOX by the log-rank test method. A total of 211 events are required in the entire study for this analysis to be feasible with a hazard ratio of 0.68. We have assumed a uniform accrual period of 38 months and further 16 months of follow-up. Clinical Trials Registry-India (CTRI) number: CTRI/2020/03/023944. The authors. TMC research administrative council Nag Foundation Metta Life Sciences Private Limited Indian Cooperative Oncology Network (ICON).
LBA8 Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Authors: N.Y. Ngoi, J-Y. Lee, Y.W. Lim, D. Lim, Y.L. Thian, A. Gopinathan, S.E. Lim, J. Low, J. Ng, P. Tong, J. Zhu, B.C. Tai, Y.J. Lee, J. Park, J-W. Kim, B-G. Kim, D.S. Tan
Journal: Annals of Oncology (2023)
392TiP A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Authors: J. Wen, J. Li, W. Zheng, J. Zhao, H. Sun, L. Chen, H. Fang, J. Zhao, J. Yang, J. Li, Y. Liu
Journal: Annals of Oncology (2023)
225P A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Authors: H.P. S, S. N, R.T. Pappala, D. Devi, A. Narikot, V.H. Veldore, N. Tanwar, P. Srikanthreddy, H. Goswami, S. Bs, A. Korlimarla
Journal: Annals of Oncology (2023)
264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: W.K. Kelly, D.C. Danila, C-C. Lin, J-L. Lee, N. Matsubara, P.J. Ward, A.J. Armstrong, D.W. Pook, M. Kim, T. Dorff, S. Fischer, Y-C. Lin, L.G. Horvath, C. Sumey, Z. Yang, G. Jurida, J. Connarn, H. Penny, J. Stieglmaier, L.J. Appleman
Journal: Annals of Oncology (2023)
352TiP Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Authors: T. Suzuki, D. Maruyama, R. Machida, Y. Ito, K. Kataoka, H. Nagai
Journal: Annals of Oncology (2023)
256O Prostate-specific antigen response to different real-world treatments in high-risk metastatic hormone-naïve prostate cancer in J-ROCK registry study
Authors: A. Mizokami, R. Matsumoto, K. Fujimoto, H. Miyake, H. Uemura, H. Uemura, S. Kawakami, K. Nakamura, S. Maekawa, K. Shibayama, Y. Tajima, T. Kamoto, H. Matsuyama
Journal: Annals of Oncology (2023)
238P Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Authors: H. Mikami, Y. Endo, J. Akatsuka, G. Kimura, H. Takeda, S. Ikuma, M. Taniuchi, H. Hasegawa, Y. Toyama, M. Shibasaki, Y. Kondo
Journal: Annals of Oncology (2023)
214P Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Authors: H. Xu, S. Wang, D. Xue, Z. Xu, Q. Zhang, Q. Wo, B. Huang, Z. Mao, F. Liu, S. Lou, J. Yuan, S. Zhu, Y. Wo, Z. Luo, J. Chen, Q. Xu, G. Li, X. Qi, D. Ye
Journal: Annals of Oncology (2023)
254TiP Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Authors: Y. Miura, K. Fujita, T. Ichikawa, S. Tamada, N. Sassa, K. Kobayashi, H. Azuma, H. Hasumi, C. Ohe, M. Eto, M. Oya, T. Kamba, N. Shinohara, T. Tsuzuki, N. Nonomura, S. Hinotsu, Y. Fujii, G. Kimura, H. Uemura
Journal: Annals of Oncology (2023)
262MO Prognostic significance of deep and rapid prostate-specific antigen (PSA) response with docetaxel (DOC) or abiraterone (ABI): A territory-wide real-world analysis of 574 Asian metastatic hormone-sensitive prostate cancer (mHSPC) patients
Authors: D.M.C. Poon, B. Lam, V. Tsang, M.P. Lee, C.L. Tz, B. Ng, B. Wo, K.C. Leung, H.C.M. Lam, W.H. Mui, T. Chan, S. Siu, K. Chan
Journal: Annals of Oncology (2023)
325TiP A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Authors: M.C. Lim, J.H. Kim, B. Park, J-Y. Park, J-Y. Lee, S-J. Chang, Y-Y. Lee, D.G. Hong, S-Y. Park
Journal: Annals of Oncology (2023)
188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Authors: M. Rimini, E. Amadeo, F. Vitiello, S. Foti, M. Persano, T. Tada, G. Suda, S. Shimose, M. Kudo, J. Cheon, F. Finkelmeier, H.Y. Lim, F. Piscaglia, G. Masi, C. Yoo, S. Lonardi, F. Rossari, S. Camera, A. Casadei Gardini, J. Presa
Journal: Annals of Oncology (2023)
244P Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Authors: S. Roy, B. Biswas, D. Dabkara, S. Ganguly, J. Ghosh, A. Bhattacharjee, S. Pal, J. Karmakar, K. Ray, S. Mandal, Y.S. Patel
Journal: Annals of Oncology (2023)
272P Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Authors: M.Z. Sabran, C.E.O.L. Hutauruk, M.D. Sembiring, C.A. Sutedja, E. Budiarti, Y.A.P. Ontowirjo, N.B.S.A. Purushotama, A. Kurniawan
Journal: Annals of Oncology (2023)
327TiP A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Authors: S. Parampalli, S. Khurana, A. Kumar, P. Malik, R. Pramanik, S. Mathur, M. Kumar, N. Bhatla, M. Ray
Journal: Annals of Oncology (2023)
232P The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Authors: S. Alzghoul, E. Al Masoud, L. Lataifeh, B. Abu Mousa, A.H. Al Sharie
Journal: Annals of Oncology (2023)
223P Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Authors: N. Oliveira, B.C.W. Li, M. Kim, I. Park, A. Dsouza, S. Chua, E.M. Tan, C. Spiteri, Y-L. Su, C.K. Yang, A. Zhang, K.C.W. Wong
Journal: Annals of Oncology (2023)
206TiP SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Authors: S.L. Chan, B. Sangro, M. Kudo, A. Dane, C. Emery, M. Paskow, M. Makowsky, B. Nguyen, L. Rimassa
Journal: Annals of Oncology (2023)
289MO Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study
Authors: X. Wu, D. Wang, J. Wang, Y. Huang, T. Yi, G. Li, J. Zhang, K. Wang, Y. Kang, A. Liu, X. Han, P. Lu, H. Shi, P. Tan, S. Fan, M. Shi, W. Su
Journal: Annals of Oncology (2023)
255O Darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
Authors: S. Wang, C. Fu, Y. Li, J. Xing, L. Zhou, Y. Yang, H. Wang, M.R. Smith, B. Tombal, M. Hussain, Y. Niu, L. Cai, Q. Liu, N. Littleton, R. Li, D. Ye
Journal: Annals of Oncology (2023)
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Authors: Z. Ren, G. Shao, J. Shen, L. Zhang, X. Zhu, W. Fang, G. Sun, Y. Bai, J. Wu, L. Liu, Y. Yuan, J. Zhang, Z. Li, L. Zhang, T. Yin, J. Wu, X. Hou, Q. Wang, J. Zhu, J. Fan
Journal: Annals of Oncology (2023)
205TiP IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Authors: T. Yamashita, Y. Inaba, M. Ikeda, M. Sone, K. Yamakado, H. Nishiofuku, K. Tsuchiya, T. Tada, Y. Sato, T. Kodama, T. Kuzuya, S. Ogasawara, M. Ueno, H. Iwamoto, M. Moriguchi, K. Ueshima, Y. Kodama, T. Takehara, T. Hamano, M. Kudo
Journal: Annals of Oncology (2023)
185P Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Authors: F. Rossari, T. Tada, S. Shimose, M. Kudo, C. Yoo, J. Cheon, F. Finkelmeier, H.Y. Lim, J. Presa, G. Masi, F. Bergamo, E. Amadeo, F. Vitiello, S. Foti, M. Persano, F. Piscaglia, M. Scartozzi, S. Cascinu, M. Rimini, A. Casadei Gardini
Journal: Annals of Oncology (2023)
184P Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Authors: Y. Sonoda, T. Araki, M. Shimokawa, T. Otsuka, T. Shibuki, J. Nakazawa, S. Arima, K. Miwa, F. Koga, Y. Ueda, Y. Kubotsu, H. Shimokawa, S. Takeshita, K. Nishikawa, A. Hosokawa, H. Oda, S. Arita, T. Shirakawa, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2023)
270P Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Authors: S. Maekawa, R. Takata, T. Matsuura, D. Ikarashi, R. Kato, M. Kanehira, J. Sugimura, W. Obara
Journal: Annals of Oncology (2023)
258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
Authors: M. Saad, K.N. Chi, S.K. Sandhu, G. Attard, D. Ye, L. Li, W. Jung, S-T. Pang, P.S.J. Francis, S. Li, S. Dibaj, J. Zhang, W. Kim, A. Lopez-Gitlitz, D. Wu, A. Singh, R. De Vries, L. Zhang, J.Y. Lee
Journal: Annals of Oncology (2023)
251P LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Authors: H. Takeda, G. Kimura, M. Taniuchi, H. Hasegawa, H. Mikami, J. Akatsuka, Y. Endo, Y. Toyama, Y. Kondo
Journal: Annals of Oncology (2023)
246P Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Authors: S. Wakeling, A. Inderjeeth, A.J. Weickhardt, J. Lynam, P. Gibbs, S. O'Haire, K. Zlatic, S.S.L. Wong, S. Sengupta, P. Manohar, A. Zhang, L-M. Wong, B. Tran, C.J. Conduit
Journal: Annals of Oncology (2023)
323P Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Authors: W.W.W.I. Gede, I.G.K.A. Sadeva, N.P.S.I. Remitha, I.G.A.S. Sadvika, I.N.B. Mahendra, D.M. Wihandani, I.G.P. Supadmanaba
Journal: Annals of Oncology (2023)
287MO Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
Authors: S. Roy, J. Ghosh, A. Bhattacharjee, S. Ganguly, B. Biswas, Y.S. Patel, S. Pal, J. Karmakar, D. Mishra, S. Vinarkar, I. Dey, R. Demde, J. Bhaumik, A. Ghosh, B. Chakraborti
Journal: Annals of Oncology (2023)
265P The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI and targeted biopsies: Real-world evidence from 2018 to 2022
Authors: H. Vigneswaran, H. Söderbäck, F. Jäderling, M. Bergman, H. Grönberg, T. Palsdottir
Journal: Annals of Oncology (2023)
215P Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Authors: T. Huang, L. Jiang, W. Wei, X. Zheng, Z. Zhang, S. Guo, H. Han, X. Cai, F. Zhou, P. Dong
Journal: Annals of Oncology (2023)
87TiP Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Authors: S. Ulahannan, M.L. Johnson, M.C. Weiss, A. Vandross, S. Vidal-Cardenas, M. Syed, A.W. Tolcher
Journal: Annals of Oncology (2023)
183P Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Authors: E. Oki, M. Ota, H. Saeki, M. Shimokawa, T. Yoshizumi, Y. Kakeji, H. Baba
Journal: Annals of Oncology (2023)